2WARFIELD CA, FAUSETT HJ. Manual of pain management[M].北京:人民卫生出版社,2005:174.
3DEBRUYNE FM, HEESAKKERS JP. Clinical and socioeconom- ic relevance of overactive bladder[J]. Urology, 2004, 63:42-44.
4MILSOM I, ABRAMS P, CARDOZO L, et al. How widespread are the SyMptoMs of an overactive blaadder and how are they managed? A population-based prevalence study[J]. BJU Int, 2010, 87 fl60-766.
5MICHEL MC. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha- blockers in the treatment of male voiding dysfunction-how do they work and why do they differ in tolerability[J]. J Pharmacol Sci, 2010, 112:151-157.
6YONO M, YAMAMOTO Y, YOSHIDA M, et al. Effects of doxazosin on blood flow and MRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary traet [J]. Life Sci, 2007, 81： 218-222.
7LAU DH, THOMPSON CS, BELLRINGER JF, et al. Doxazos- in and serotonin (5-HT) receptor (1A, 2A, and 4) antagonists inhibit 5-HT mediated human cavernosal contraction[J]. J An- dro, 2006, 27: 679-685.
